Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Roche’s al­pha-synu­cle­in-tar­get­ing an­ti­body has failed to slow the pro­gres­sion of mo­tor symp­toms in a mid-stage Parkin­son’s dis­ease test, mark­ing the lat­est set­back in a large­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER